The truncated chromosome 22 that results from the reciprocal translocation t (9; 22)(q34;
q11) is known as the Philadelphia chromosome (Ph) and is a hallmark of chronic myeloid …

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level.
Chromosomal abnormalities are used as diagnostic, prognostic and predictive biomarkers to …

The number of cancer survivors continues to increase because of both advances in early
detection and treatment and the aging and growth of the population. For the public health …

Background Treatment with rituximab has improved the outcome for patients with non-
Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

Clinical oncology is being revolutionized by the increasing use of molecularly targeted
therapies. This paradigm holds great promise for improving cancer treatment; however …

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for
patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) …

BACKGROUND Older adults with relapsed/refractory B‐precursor acute lymphoblastic
leukemia (r/r ALL) are reported to have a poor prognosis and few therapeutic options. In the …

In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia
patients were treated with chemotherapy for induction and consolidation, followed by …

Background Persons with acute leukemia relapsing after allotransplant and who respond to
anti-leukemia interventions are at high risk of a second relapse. We studied the impact of …